Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Advances in Antidiabetic Drugs Targeting Insulin Secretion

Author(s): Yanting Ding, Yilian Li, Qin Chen* and Bing Niu*

Volume 24, Issue 34, 2018

Page: [3990 - 3997] Pages: 8

DOI: 10.2174/1381612824666181112113756

Price: $65

Abstract

Background: Diabetes mellitus (DM) is a disease of systemic metabolic disorders caused by the decrease of secretion or sensitivity of insulin. In recent years, the study of insulin-related drug targets and the development of new drugs have become the popular topic of current medical research, and studies have shown that multiple signaling pathways are associated with diabetes treatment. At present, some new drugs based on the new target design have been listed on the market and have achieved good hypoglycemic effect. However, most of the drugs are still in the clinical or pre-clinical stage. The efficacy and safety of the drugs need further clinical validation.

Objective: This article will introduce the advancements of targets and drugs to promote insulin secretion.

Keywords: Diabetes mellitus, antidiabetic drugs, GLP-1R, KATP, GPR119, insulin.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy